首頁 > 市場調查報告書 > 醫療設備

體外診斷

市場調查報告書

商品編碼

2126354

敗血症診斷市場：策略性洞察與預測（2026-2035 年）

Sepsis Diagnostics Market - Strategic Insights and Forecasts (2026-2035)

出版日期: 2026年08月05日 | 出版商:

Knowledge Sourcing Intelligence | 英文 175 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄

預計敗血症診斷市場將從 2026 年的 71 億美元成長到 2035 年的 159.3 億美元，複合年成長率為 9.4%。

敗血症診斷市場正經歷著重大變革，其驅動力在於對快速、準確的診斷資訊的需求，以改善危及生命的感染疾病的臨床療效。這一市場演變的特點是模式轉移，從傳統的培養方法轉向分子診斷、基於生物標記的決策以及整合自動化系統。隨著疾病進展加速，治療效果會下降，因此早期發現敗血症是醫療保健系統的重中之重，這顯著增加了對能夠縮短病原體鑑定和治療性介入延遲的快速診斷解決方案的需求。分子檢測、生物標記分析和人工智慧的融合，使得敗血症的診斷更加快速、全面且具預測性。抗菌藥物管理工作依賴準確的診斷訊息，因為不合理使用抗生素會導致抗藥性和資源緊張。監管機構正在強調臨床表現，因為診斷結果直接影響重症監護病房的病患管理。隨著對多參數分子檢測、即時診斷和人工智慧驅動的檢測平台的大量投資，敗血症診斷正逐漸成為重症監護和感染疾病管理的基石。

市場促進因素

對膿毒症早期檢測的日益重視是膿毒症診斷市場的主要驅動力。早期療育能夠改善預後，因為延遲診斷往往會導致敗血症進展和嚴重併發症。臨床醫生需要在患者評估的早期階段獲得可操作的信息，這推動了對快速檢測的需求。這種需求促使醫療系統縮短診斷時間。醫院正在實施由先進診斷技術支援的快速敗血症診療方案，從而擴大了快速診斷技術的應用範圍，並持續提高敗血症診斷的使用率。合理使用抗生素方案的推廣進一步加速了市場成長，因為它增加了對病原體準確鑑定的需求。準確識別感染對於合理使用抗生素至關重要，因為經驗性治療策略可能導致抗藥性的產生和不必要的醫療成本。隨著臨床醫生尋求更具針對性的治療方法，對能夠區分感染性和非感染性感染疾病的診斷工具的需求日益成長。這種需求推動了對分子診斷和生物標記檢測的興趣。醫療機構正在將診斷數據整合到其抗生素使用實踐中，從而提高了先進敗血症診斷技術的使用率。生物標記檢測的日益普及正在提升臨床決策能力和診斷信心。生物標記能夠輔助臨床決策，因為生理反應通常能夠提供感染嚴重程度的早期證據。隨著醫療專業人員尋求更高的診斷信心，對降鈣素原（PCT）、C反應蛋白（CRP）和多生物標記檢測的需求不斷成長。這種需求為生物標記的更廣泛應用創造了機會。診斷技術開發人員正致力於提升檢測的效能和可近性，以支援更廣泛的應用。因此，生物標記檢測在膿毒症管理流程中的整合正在不斷推進。分子診斷技術的進步使得更早的治療指南和更最佳化的診斷流程成為可能。分子診斷能夠快速檢測病原體，而傳統的培養方法則耗時較長。隨著臨床醫生尋求更早的治療指南，對聚合酶鍊式反應（PCR）和多分子檢測的需求也不斷成長。這些期望提升了能夠加速診斷流程的技術的價值。為了滿足這些需求，診斷設備製造商正在擴展其分子偵測產品線。

市場限制因素

先進的分子和自動化診斷系統實施成本高昂，需要大量資金投入，限制了其廣泛應用。這種沉重的經濟負擔對小規模的醫療機構來說是一個障礙。報銷政策的差異也限制了其使用，因為醫療服務提供者常常面臨診斷保險覆蓋範圍的不確定性。保險覆蓋範圍的區域差異也為診斷服務提供者帶來了不確定性，並限制了患者的就醫途徑。整合到臨床工作流程的挑戰也限制了其應用，因為醫院必須調整現有流程以適應新的診斷技術。將新平台整合到現有工作流程中的複雜性是其應用的一大障礙。不同司法管轄區法規的複雜性也給尋求將新診斷解決方案商業化的製造商帶來了合規負擔。

市場定義和範圍
膿毒症診斷行業概覽
產業變化
主要市場趨勢
市場規模表現分析
市場預測分析
膿毒症疾病負擔分析
對膿毒症發病率和確診患者人數的分析
加護病房（ICU）病人概況分析
膿毒症檢測案例分析
臨床路徑與病人歷程分析
合理使用抗生素和診斷技術的趨勢

第4章市場動態

市場促進因素
市場限制因素
市場機遇
市場挑戰

第5章行業情勢

產業價值鏈分析
定價分析
還款狀態

第6章：創新趨勢

敗血症診斷領域的新興技術
產品創新
臨床試驗分析
管道分析
技術藍圖
將人工智慧整合到膿毒症檢測和臨床決策支援中
數位健康整合與自動化診斷工作流程

第7章監理情勢

法律規範
核准流程
合規要求

第8章：敗血症診斷市場：展望分析

分析：按技術平台
分析：依生物標記類型
分析：檢體類型
分析：透過臨床應用
分析：透過測試方法

第9章膿毒症診斷市場：細分市場分析

按診斷類型
- 血液培養診斷
- 分子診斷
- 基於生物標記的診斷方法
- 即時診斷
- 基於微生物學的診斷方法
- 自動診斷系統
依生物標誌類型
- 抑鈣素(PCT) 檢測
- C反應蛋白（CRP）檢測
- 基於白細胞介素的生物標記檢測
- 乳酸試驗
- 前降鈣素原試驗
- 多生物標記檢測
透過技術
- 聚合酵素鏈鎖反應（PCR）
- 多重分子檢測
- 次世代定序（NGS）
- 免疫測量
- 流式細胞技術
- 基於質譜的診斷
最終用戶
- 醫院
- 加護病房
- 診斷檢查室
- 學術研究機構
- 急診中心

第10章敗血症診斷市場：區域分析

北美洲
歐洲
亞太地區
南美洲
中東和非洲

第11章：敗血症診斷市場：國別分析

美國
加拿大
德國
英國
法國
義大利
西班牙
日本
中國
印度
韓國
澳洲
巴西
沙烏地阿拉伯
南非

第12章競爭格局

市佔率分析
策略趨勢
併購、合作與聯盟
新產品發布

第13章：公司簡介

bioMerieux
Becton Dickinson and Company
Danaher Corporation
F. Hoffmann-La Roche
Abbott Laboratories
Thermo Fisher Scientific
QIAGEN
Siemens Healthineers
Sysmex Corporation
Bruker Corporation
Accelerate Diagnostics
T2 Biosystems
OraSure Technologies
Cytovale
Prenosis

第14章：敗血症診斷市場：商業預測分析

第15章投資與資金籌措分析

創業投資趨勢
政府資金
研發投資

第16章：未來展望

主要成長機遇
未來產業趨勢

簡介目錄

Product Code: KSI-009065

The Sepsis Diagnostics Market is anticipated to grow at a CAGR of 9.4% from USD 7.10 billion in 2026 to USD 15.93 billion in 2035.

The sepsis diagnostics market is undergoing significant transformation driven by the critical need for rapid and accurate diagnostic information to improve clinical outcomes in life-threatening infections. The market's evolution is characterized by the paradigm shift from conventional culture-based methods toward molecular diagnostics, biomarker-guided decision-making, and integrated automated systems. Healthcare systems are prioritizing early sepsis recognition because treatment effectiveness declines as disease progression accelerates, creating substantial demand for rapid diagnostic solutions that reduce delays in pathogen identification and therapeutic intervention. The convergence of molecular testing, biomarker analysis, and artificial intelligence is enabling faster, more comprehensive, and increasingly predictive sepsis diagnosis. Antimicrobial stewardship initiatives rely on accurate diagnostic information because inappropriate antibiotic use contributes to resistance and resource burden. Regulatory agencies emphasize clinical performance because diagnostic outcomes directly influence patient management in critical care environments. The market is witnessing significant investment in multiplex molecular testing, point-of-care diagnostics, and AI-enabled detection platforms, positioning sepsis diagnostics as a cornerstone of critical care and infectious disease management.

Market Drivers

The increasing focus on early sepsis recognition represents the primary driver for the sepsis diagnostics market. Early intervention improves outcomes because sepsis progression frequently leads to severe complications when diagnosis is delayed. Demand is increasing for rapid testing because clinicians require actionable information during the earliest stages of patient assessment. This need creates pressure on healthcare systems to reduce diagnostic turnaround times. Hospitals are implementing accelerated sepsis protocols supported by advanced diagnostics, resulting in stronger adoption of rapid diagnostic technologies and sustained growth in sepsis diagnostic utilization. The expansion of antimicrobial stewardship programs is further accelerating market growth through increased demand for accurate pathogen identification. Antibiotic stewardship depends on accurate infection identification because empirical treatment strategies can contribute to resistance and unnecessary healthcare costs. Demand is increasing for diagnostic tools that differentiate infectious and non-infectious conditions because clinicians seek more targeted treatment approaches. This requirement expands interest in molecular diagnostics and biomarker testing. Healthcare organizations are integrating diagnostic data into stewardship initiatives, resulting in increasing utilization of advanced sepsis diagnostics. The rising adoption of biomarker-based testing is strengthening clinical decision-making and diagnostic confidence. Biomarkers support clinical decision-making because physiological responses frequently provide early evidence of infection severity. Demand is increasing for PCT, CRP, and multi-biomarker testing because healthcare providers require greater diagnostic confidence. This requirement creates opportunities for expanded biomarker utilization. Diagnostic developers are advancing assay performance and accessibility to support broader adoption. The result is stronger integration of biomarker testing within sepsis management pathways. The growth of molecular diagnostic technologies is enabling earlier treatment guidance and improved diagnostic workflows. Molecular diagnostics enable rapid pathogen detection because traditional culture-based approaches may require extended processing times. Demand is increasing for PCR and multiplex molecular testing because clinicians seek earlier treatment guidance. This expectation raises the value of technologies capable of accelerating diagnostic workflows. Diagnostic companies are expanding molecular testing portfolios to address these needs.

Market Restraints

High implementation costs limit adoption because advanced molecular and automated diagnostic systems require significant capital investment. The substantial financial commitment creates barriers for smaller healthcare facilities. Variability in reimbursement policies constrains utilization because healthcare providers often face uncertainty regarding diagnostic coverage. Inconsistent coverage across regions creates uncertainty for diagnostic providers and limits patient access. Clinical workflow integration challenges restrict deployment because hospitals must adapt existing processes to accommodate new diagnostic technologies. The complexity of integrating new platforms into established workflows creates implementation barriers. Regulatory complexities across different jurisdictions create compliance burdens for manufacturers seeking to commercialize new diagnostic solutions.

Technology and Segment Insights

The technology landscape is characterized by the growing importance of integrated diagnostic approaches combining multiple modalities. Demand is increasing for PCR and multiplex molecular testing because rapid pathogen identification improves treatment decisions. This requirement raises interest in NGS and advanced immunoassays. Blood culture diagnostics remain the reference standard for bloodstream infection identification. Biomarker-based diagnostics, including PCT, CRP, and multi-biomarker panels, support clinical decision-making and risk stratification. Point-of-care diagnostics are gaining relevance because emergency settings require immediate clinical information. Automated diagnostic systems are improving laboratory efficiency and workflow standardization. The segment analysis reveals that molecular diagnostics are experiencing strong growth because clinicians seek earlier pathogen identification than conventional culture methods often provide. Biomarker testing supports clinical confidence because sepsis diagnosis often requires evidence beyond observable symptoms. Demand is increasing for PCT testing because clinicians seek improved differentiation between bacterial infection and other inflammatory conditions. Hospitals represent the primary end-user segment, with intensive care units and emergency care centers driving demand for rapid diagnostics. Diagnostic laboratories are expanding testing capacity to accommodate growing demand. The integration of AI is becoming increasingly important because clinical datasets continue expanding as healthcare systems capture real-time patient information. Technology providers are integrating machine learning into clinical workflows to improve decision support.

Competitive and Strategic Outlook

The competitive landscape features established diagnostics and life science companies alongside specialized sepsis diagnostics and AI-enabled platforms. bioMerieux remains strategically distinct because it combines leadership in clinical microbiology with a strong focus on infectious disease diagnostics and antimicrobial stewardship, continuing to expand automated microbiology capabilities and strengthen software and laboratory informatics offerings. BD remains strategically distinct because its blood culture technologies occupy a central role in sepsis diagnosis across healthcare systems, enhancing automation and laboratory efficiency while developing solutions that improve pathogen detection and susceptibility assessment. Danaher remains strategically distinct because its healthcare businesses provide technologies spanning molecular diagnostics, microbiology, life sciences, and laboratory automation, continuing to invest in automation and advanced diagnostic technologies to address integrated workflow requirements. Roche remains strategically distinct because it combines extensive expertise in molecular diagnostics, laboratory testing, and healthcare innovation, continuing to advance molecular and laboratory technologies while strengthening laboratory automation capabilities. QIAGEN possesses extensive expertise in molecular diagnostics and sample-to-result workflow technologies, strengthening infectious disease diagnostic capabilities through technological innovation and strategic collaborations. Siemens Healthineers combines laboratory diagnostics, biomarker testing, and healthcare informatics capabilities, continuing to expand diagnostic offerings designed to improve clinical efficiency and patient management. Sysmex integrates hematology expertise with expanding infectious disease diagnostic capabilities, advancing technologies that support rapid clinical assessment and laboratory efficiency. Companies are pursuing product portfolio expansion through innovation in molecular diagnostics, biomarker panels, and AI-enabled detection platforms. Strategic collaborations between diagnostic manufacturers and healthcare systems are increasing, driven by the need for early sepsis recognition and antimicrobial stewardship. Geographic expansion remains a key strategic priority, with companies targeting rapidly growing Asia Pacific and emerging markets where healthcare infrastructure is expanding.

Short Conclusion

The sepsis diagnostics market is positioned for sustained growth driven by the convergence of early recognition initiatives, antimicrobial stewardship, and technological innovation. The transition from conventional culture-based methods toward integrated molecular and biomarker platforms represents a fundamental evolution in critical care diagnostics. While challenges related to high costs, reimbursement variability, and workflow integration persist, strategic investments in technology, automation, and partnerships are creating durable competitive advantages for market leaders. The long-term market outlook remains positive, with sepsis diagnostics evolving into a cornerstone of critical care and infectious disease management, supporting rapid pathogen identification, biomarker-guided decision-making, and improved patient outcomes across global healthcare systems.

Key Benefits of this Report

Insightful Analysis: Detailed market insights across regions, customer segments, policies, socio-economic factors, consumer preferences, and industry verticals.
Competitive Landscape: Understand strategic moves by key players to identify optimal market entry approaches.
Market Drivers and Future Trends: Assess major growth forces and emerging developments shaping the market.
Actionable Recommendations: Support strategic decisions to unlock new revenue streams.
Caters to a Wide Audience: Suitable for startups, research institutions, consultants, SMEs, and large enterprises.

What Businesses Use Our Reports For

Industry and market insights, opportunity assessment, product demand forecasting, market entry strategy, geographical expansion, capital investment decisions, regulatory analysis, new product development, and competitive intelligence.

Report Coverage

Historical data from 2021 to 2024, Base year 2025, and Forecast years from 2026 to 2035
Growth opportunities, challenges, supply chain outlook, regulatory framework, and trend analysis
Competitive positioning, strategies, and market share evaluation, and trade analysis
Revenue growth and forecast assessment across segments and regions
Company profiling including strategies, products, financials, and key developments

1. Executive Summary

1.1 Market Snapshot
1.2 Key Findings
1.3 Analyst Insights
1.4 Strategic Recommendations

2. Research Methodology

2.1 Research Design
2.2 Data Collection Methodology
2.3 Market Size Estimation
2.4 Forecasting Model
2.5 Assumptions & Limitations

3. Sepsis Diagnostics Market Overview, Size & Forecast

3.1 Market Definition & Scope
3.2 Sepsis Diagnostics Industry Overview
3.3 Industry Evolution
3.4 Key Market Trends
3.5 Historical Market Size Analysis (2021-2025)
3.6 Market Forecast Analysis (2026-2035)
3.7 Sepsis Disease Burden Analysis
3.8 Sepsis Incidence and Diagnosed Patient Population Analysis
3.9 Intensive Care Unit (ICU) Patient Population Analysis
3.10 Sepsis Testing Volume Analysis
3.11 Clinical Pathway and Patient Journey Analysis
3.12 Antimicrobial Stewardship and Diagnostic Utilization Trends

4. Market Dynamics

4.1 Market Drivers
4.2 Market Restraints
4.3 Market Opportunities
4.4 Market Challenges

5. Industry Landscape

5.1 Industry Value Chain Analysis
5.2 Pricing Analysis
5.3 Reimbursement Landscape

6. Innovation Landscape

6.1 Emerging Technologies in Sepsis Diagnostics
6.2 Product Innovation
6.3 Clinical Trial Analysis
6.4 Pipeline Analysis
6.5 Technology Roadmap
6.6 AI Integration in Sepsis Detection and Clinical Decision Support
6.7 Digital Health Integration and Automated Diagnostic Workflows

7. Regulatory Landscape

7.1 Regulatory Framework
7.2 Approval Pathways
7.3 Compliance Requirements

8. Sepsis Diagnostics Market Landscape Analysis

8.1 Analysis by Technology Platform
8.2 Analysis by Biomarker Type
8.3 Analysis by Sample Type
8.4 Analysis by Clinical Application
8.5 Analysis by Testing Methodology

9. Sepsis Diagnostics Market Segment Analysis (2021-2035)

9.1 By Diagnostic Type
- 9.1.1 Blood Culture Diagnostics
- 9.1.2 Molecular Diagnostics
- 9.1.3 Biomarker-Based Diagnostics
- 9.1.4 Point-of-Care Diagnostics
- 9.1.5 Microbiology-Based Diagnostics
- 9.1.6 Automated Diagnostic Systems
9.2 By Biomarker Type
- 9.2.1 Procalcitonin (PCT) Testing
- 9.2.2 C-Reactive Protein (CRP) Testing
- 9.2.3 Interleukin-Based Biomarker Testing
- 9.2.4 Lactate Testing
- 9.2.5 Presepsin Testing
- 9.2.6 Multi-Biomarker Panels
9.3 By Technology
- 9.3.1 Polymerase Chain Reaction (PCR)
- 9.3.2 Multiplex Molecular Testing
- 9.3.3 Next-Generation Sequencing (NGS)
- 9.3.4 Immunoassays
- 9.3.5 Flow Cytometry
- 9.3.6 Mass Spectrometry-Based Diagnostics
9.4 By End User
- 9.4.1 Hospitals
- 9.4.2 Intensive Care Units
- 9.4.3 Diagnostic Laboratories
- 9.4.4 Academic and Research Institutes
- 9.4.5 Emergency Care Centers